The Role of Clusterin in Alzheimer’s Disease: Pathways, Pathogenesis, and Therapy
Abstract
Genetic variation in clusterin gene, also known as apolipoprotein J, has been associated with Alzheimer's disease (AD) through replicated genome-wide studies, and plasma clusterin levels are associated with brain atrophy, baseline prevalence and severity, and rapid clinical progression in patients with AD, highlighting the importance of clusterin in AD pathogenesis. Emerging data suggest that clusterin contributes to AD through various pathways, including amyloid-β aggregation and clearance, lipid metabolism, neuroinflammation, and neuronal cell cycle control and apoptosis. Moreover, epigenetic regulation of the clusterin expression also seems to play an important role in the pathogenesis of AD. Emerging knowledge of the contribution of clusterin to the pathogenesis of AD presents new opportunities for AD therapy.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
By binding to its major receptor LRP2, the CLU-Aβ complex can be eliminated from the brain.
“By binding to its major receptor - LRP2, the CLU-Aβ complex can then be eliminated from the brain [64].”
From Sex specific molecular networks and key drivers of Alzheimer’s disease (2023) · cites this paper as [64]
CLU is able to bind a variety of physiological ligands, including Aβ, due to its flexible structures.
“With its flexible structures, CLU is able to bind a variety of physiological ligands, including Aβ [64].”
From Sex specific molecular networks and key drivers of Alzheimer’s disease (2023) · cites this paper as [64]
Cites
Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6448 · Cited by 3,506 · see citing works
Harold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M. L., Pahwa, J. S., Moskvina, V., Dowzell, K., Williams, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.440 · Cited by 3,326 · see citing works
Naj, A. C., Jun, G., Beecham, G. W., Wang, L.-S., Vardarajan, B. N., Buros, J., Gallins, P. J., Buxbaum, J. D., Jarvik, G. P., Crane, P. K., et al. (2011) · Nature Genetics · doi:10.1038/ng.801 · Cited by 1,901 · see citing works
Nonsteroidal Antiinflammatory Drugs and the Risk of Alzheimer's Disease
in 't Veld, B. A., Ruitenberg, A., Hofman, A., Launer, L. J., van Duijn, C. M., Stijnen, T., Breteler, M. M. B., & Stricker, B. H. C. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010178 · Cited by 1,196 · see citing works
Oda, T., Wals, P., Osterburg, H. H., Johnson, S. A., Pasinetti, G. M., Morgan, T. E., Rozovsky, I., Stine, W. B., Snyder, S. W., Holzman, T. F., et al. (1995) · Experimental Neurology · doi:10.1006/exnr.1995.1080 · Cited by 352 · see citing works
May, P. C., Lampert-Etchells, M., Johnson, S. A., Poirier, J., Masters, J. N., & Finch, C. E. (1990) · Neuron · doi:10.1016/0896-6273(90)90342-d · Cited by 339 · see citing works
Corneveaux, J. J., Myers, A. J., Allen, A. N., Pruzin, J. J., Ramirez, M., Engel, A., Nalls, M. A., Chen, K., Lee, W., Chewning, K., et al. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq221 · Cited by 237 · see citing works
Replication of CLU, CR1, and PICALM Associations With Alzheimer Disease
Carrasquillo, M. M., Belbin, O., Hunter, T. A., Ma, L., Bisceglio, G. D., Zou, F., Crook, J. E., Pankratz, V. S., Dickson, D. W., Graff-Radford, N. R., et al. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.147 · Cited by 208 · see citing works
Kirszbaum, L., Bozas, S. E., & Walker, I. D. (1992) · FEBS Letters · doi:10.1016/0014-5793(92)80330-j · Cited by 76 · cited 1× · see citing works
“Several studies have suggested that clusterin is involved directly and indirectly in numerous ways related to inflammation and immunities, also in brain [80, 81]: (a) regulation of complement activation [82, 83], (b) negative regulator of NF-κB [84, 85], and (c) activation of microglia and bidirectional regulation of…”
Apolipoprotein J (clusterin) activates rodent microglia <i>in vivo</i> and <i>in vitro</i>
Xie, Z., Harris‐White, M. E., Wals, P. A., Frautschy, S. A., Finch, C. E., & Morgan, T. E. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03065.x · Cited by 53 · cited 1× · see citing works
“Several studies have suggested that clusterin is involved directly and indirectly in numerous ways related to inflammation and immunities, also in brain [80, 81]: (a) regulation of complement activation [82, 83], (b) negative regulator of NF-κB [84, 85], and (c) activation of microglia and bidirectional regulation of…”
Flagged first, then by citations
Cited by
Sorted by citations
The epigenetics of aging and neurodegeneration
Lardenoije, R., Iatrou, A., Kenis, G., Kompotis, K., Steinbusch, H. W. M., Mastroeni, D., Coleman, P., Lemere, C. A., Hof, P. R., van den Hove, D. L. A., et al. (2015) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.05.002 · Cited by 381 · see citing works
Exercise benefits on Alzheimer’s disease: State-of-the-science
Valenzuela, P. L., Castillo-García, A., Morales, J. S., de la Villa, P., Hampel, H., Emanuele, E., Lista, S., & Lucia, A. (2020) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101108 · Cited by 337 · see citing works
Glial activation and inflammation along the Alzheimer’s disease continuum
Nordengen, K., Kirsebom, B.-E., Henjum, K., Selnes, P., Gísladóttir, B., Wettergreen, M., Torsetnes, S. B., Grøntvedt, G. R., Waterloo, K. K., Aarsland, D., et al. (2019) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1399-2 · Cited by 274 · see citing works
Watson, C. T., Roussos, P., Garg, P., Ho, D. J., Azam, N., Katsel, P. L., Haroutunian, V., & Sharp, A. J. (2016) · Genome Medicine · doi:10.1186/s13073-015-0258-8 · Cited by 201 · see citing works
Zhao, L., Mao, Z., Woody, S. K., & Brinton, R. D. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.02.011 · Cited by 132 · see citing works
Kim, D. K., Park, J., Han, D., Yang, J., Kim, A., Woo, J., Kim, Y., & Mook-Jung, I. (2018) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0234-4 · Cited by 95 · see citing works
The Role of Clusterin in Amyloid-β–Associated Neurodegeneration
Desikan, R. S., Thompson, W. K., Holland, D., Hess, C. P., Brewer, J. B., Zetterberg, H., Blennow, K., Andreassen, O. A., McEvoy, L. K., Hyman, B. T., et al. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2013.4560 · Cited by 79 · see citing works
Commentary: is Alzheimer's disease uniquely human?
Finch, C. E., & Austad, S. N. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.10.025 · Cited by 72 · see citing works
Sex specific molecular networks and key drivers of Alzheimer’s disease
Guo, L., Cao, J., Hou, J., Li, Y., Huang, M., Zhu, L., Zhang, L., Lee, Y., Duarte, M. L., Zhou, X., et al. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00624-5 · Cited by 49 · see citing works
Katsumata, Y., Nelson, P. T., Estus, S., & Fardo, D. W. (2019) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.10.017 · Cited by 30 · see citing works
Differential effects of apoE4 and activation of ABCA1 on brain and plasma lipoproteins
Boehm-Cagan, A., Bar, R., Harats, D., Shaish, A., Levkovitz, H., Bielicki, J. K., Johansson, J. O., & Michaelson, D. M. (2016) · PLOS ONE · doi:10.1371/journal.pone.0166195 · Cited by 29 · see citing works
- Authors
- Yu, J.-T., & Tan, L.
- Affiliations
- Qingdao University (CN)
- Corresponding author
- Yu, Jin-Tai
- Tan, Lan
- ORCID
- Venue
- Molecular Neurobiology
- Published
- 2012-01-25
- Volume
- 45
- Issue
- 2
- Pages
- 314-326
- ISSN
- 0893-7648 (ISSN-L)
- 1559-1182
- OpenAlex
- W2031157188
- Cited by
- 174
- References
- 10
- Citations by year
- 2026: 6 · 2025: 7 · 2024: 25 · 2023: 9 · 2022: 14 · 2021: 9 · 2020: 11 · 2019: 8 · 2018: 15 · 2017: 10 · 2016: 15 · 2015: 22 · 2014: 11 · 2013: 10 · 2012: 2
- FWCI
- 1.55
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Molecular Neurobiology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Oncology › Clusterin in disease pathology
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- clusterin, Alzheimer's disease, amyloid-beta aggregation, amyloid-beta clearance, lipid metabolism, neuroinflammation, apoptosis, epigenetic regulation, genetic association, plasma biomarkers, brain atrophy, disease progression, Alzheimer's disease treatment
- MeSH terms
- Alzheimer Disease, Animals, Brain, Humans, Clusterin, Metabolic Networks and Pathways
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
